avacincaptad pegol

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

EENT: conjunctival hemorrhage, blepharitis, blurred vision, endophthalmitis, eye pain, ↑intraocular pressure, neovascular age-related macular degeneration, retinal detachment, vitreous floaters

Interactions ⬆ ⬇

Drug-drug:

Availability ⬆ ⬇

Route/Dosage ⬆ ⬇

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Binds to and inhibits complement protein C5, which ultimately decreases the formation of membrane attack complex.

Therapeutic effects:

Classifications ⬆ ⬇

Therapeutic Classification: ocular agents

Pharmacologic Classification: complement.inhibitors

Pharmacokinetics ⬆ ⬇

Absorption: Intravitreal administration results in complete local bioavailability. Very low serum levels are achieved.

Distribution: Minimal distribution outside of intravitreal space.

Metabolism/Excretion: Catabolized by endonucleases and exonucleases to oligonucleotides of shorter lengths. Excreted renally.

Half-Life: 12 days.

Time/Action Profile ⬆ ⬇

(intravitreal concentrations)

ROUTE	ONSET	PEAK	DURATION
intravitreal	unknown	7 days	unknown

Patient/Family Teaching ⬆ ⬇

Explain the purpose of avacincaptad and possible side effects. Do not stop receiving avacincaptad without consulting health care professional. If an appointment is missed, contact health care professional as soon as possible to reschedule. Advise patient to read Medication Guide before starting and periodically during therapy in case of changes.
Explain that subconjunctival hemorrhage is a common and benign temporary occurrence with eye injections.
Emphasize the importance of follow-up exams to evaluate progress.
Discuss possible temporary blurred vision; advise patient to avoid driving or other activities requiring clear vision until response to medication is known.
Advise patient to immediately report and seek treatment for signs and symptoms of eye or periorbital infections (pain, redness, discharge, swelling, light sensitivity, blurry vision, itchiness, eye bulging, fever).
Advise patient risk of permanent vision loss if retinal detachment occurs; immediately seek treatment for symptoms of floaters, curtain-like shadows, flashes of light in vision.
Advise patient to report signs and symptoms of macular degeneration (central vision loss, dark or blind spots, visual distortions in one or both eyes) or ↑ IOP (eye pain, eye redness, blurry vision, seeing halos around lights, light sensitivity, headaches).
Rep: Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.